We are a global, science-led, patient-focused pharmaceutical company. We are dedicated to transforming the future of healthcare by unlocking the power of what science can do for people, society and the planet.
Our business is organised to deliver our growth through innovation strategy and achieve our purpose of pushing the boundaries of science to deliver life-changing medicines.
Our R&D and Commercial functions promote accelerated decision making and the launches of new medicines across our therapy areas.
AstraZeneca AB is a global biopharmaceutical company headquartered in Sweden. The company was formed in 1999 through the merger of the Swedish company Astra and the British company Zeneca. AstraZeneca is dedicated to the research, development, production, and marketing of a wide range of medications across various therapeutic areas, including cardiovascular, metabolic diseases, respiratory, inflammation, autoimmune, oncology, and more. Their research focuses on biomedical and drug innovation to improve the health outcomes of patients.
AstraZeneca has a global presence with business operations and research centers worldwide. Their portfolio includes several popular prescription drugs and biologics.
AstraZeneca AB has a diverse portfolio of prescription drugs across various therapeutic areas. Some of their popular and widely known prescription drugs include:
- Nexium (esomeprazole): Used to treat gastroesophageal reflux disease (GERD) and other conditions involving excessive stomach acid.
- Crestor (rosuvastatin): A statin medication used to lower cholesterol levels.
- Symbicort (budesonide/formoterol): A combination inhaler used to manage asthma and chronic obstructive pulmonary disease (COPD).
- Farxiga (dapagliflozin): An oral medication used to treat type 2 diabetes by helping the kidneys remove glucose from the bloodstream.
- Tagrisso (osimertinib): A targeted therapy used for the treatment of certain types of non-small cell lung cancer (NSCLC).
- Imfinzi (durvalumab): An immune checkpoint inhibitor used in the treatment of various cancers, including lung cancer.
- Lynparza (olaparib): A PARP inhibitor used in the treatment of certain ovarian, breast, and pancreatic cancers.
- Brilinta (ticagrelor): An antiplatelet medication used to prevent blood clots in patients with acute coronary syndrome.
- Zoladex (goserelin): Used in the treatment of prostate cancer, breast cancer, and certain gynecological conditions.
- Faslodex (fulvestrant): Used to treat hormone receptor-positive metastatic breast cancer.
AstraZeneca plc is an English pharmaceutical company located in Cambridge. It is a multinational pharmaceutical and biotechnology firm based in the United Kingdom and Sweden. The company operates in over 100 countries and caters to the requirements of millions of people globally. Among the significant ailments covered by the company’s product range are oncology, gastrointestinal, infectious, respiratory, and inflammatory disorders. Astra AB and Zeneca Group Plc amalgamated to establish AstraZeneca in 1999.
Astra AB was founded in 1913 by 400 Swedish doctors. Zeneca Group PLC was created in 1993 when the British chemicals business ICI (formed by the amalgamation of four British chemical companies) demerged its medicines, agrochemicals, and specialist divisions to become Zeneca Group PLC. The merger is one of the world’s largest pharmaceutical businesses, having purchased several corporations, including Cambridge Antibody Technology (in 2006), MedImmune (in 2007), Spirogen (in 2013), and Definiens (by MedImmune in 2014).
The organisation undertakes research and development in three strategic locations: England, Sweden, and Maryland, United States. The Oxford–AstraZeneca vaccine was approved for use in India in January 2021, paving the way for a large-scale vaccination campaign in the world’s second-most populous country.
Address：
Karlebyhus, Astraallen
Sodertalje 26 SE‐151‐85 SWEDEN
Product Approval Dates:
03‐MAY‐2018 Coagulation Factor Xa (Recombinant), Inactivated‐zhzo